Three new coronary pneumonia vaccines have completed Phase II clinical trials in China

Three new coronary pneumonia vaccines have completed Phase II clinical trials in China

The Ministry of Science and Technology and the National Health and Health Commission announced on June 19 that China has already approved 5 new crown vaccines for clinical trials, accounting for 40% of the total clinical trial vaccines in the world. It is expected that other technical route vaccines will be approved in the near future. Clinical Trials. my country's scientific research team has deployed a total of 12 vaccine development tasks in accordance with five technical routes including inactivated vaccines, genetically engineered subunit vaccines, adenovirus vector vaccines, attenuated influenza virus vector vaccines, and nucleic acid vaccines. At present, clinical trials have been carried out on one adenoviral vector vaccine and four inactivated vaccines, accounting for 40% of the total number of clinical trials in the world. Among them, 3 new coronary pneumonia vaccines made new progress and completed the second phase of clinical trials.